In addition, Tocilizumab, which antagonises IL-6 function by targeting IL-6R, has been shown to beneficially affect survival and clinical outcomes in the treatment of COVID-19 patients with severe pneumonia [9,10]. The gene discussed is IL6; the disease is COVID-19.